Shorter steroid course may be just as effective for giant cell arteritis

NCT ID NCT04012905

Recruiting now Disease control Sponsor: University Hospital, Caen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a shorter, lighter course of corticosteroids (28 weeks) works as well as the standard longer course (52 weeks) for giant cell arteritis, a condition that inflames blood vessels. The study aims to reduce side effects from long-term steroid use. 150 newly diagnosed patients will be randomly assigned to one of the two tapering schedules and followed for a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Corticosteroids (prednisone)
What this could lead to: If successful, this could show that a shorter course of steroids works just as well as a longer one, reducing side effects for patients with giant cell arteritis.
What could go wrong: This is a relatively small trial (150 people) and only compares two steroid tapering schedules, not a new treatment. The shorter course may lead to more relapses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis Recurrence temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS

Contacts and locations

Locations

CHU de Caen Normandie
RECRUITING

Caen, 14000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.